Last reviewed · How we verify

Universidad Nacional de Salta — Portfolio Competitive Intelligence Brief

Universidad Nacional de Salta pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Albendazole Pill Albendazole Pill phase 3 Benzimidazole anthelmintic β-tubulin Infectious Disease / Parasitology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Lihir Medical Centre · 1 shared drug class
  2. London School of Hygiene and Tropical Medicine · 1 shared drug class
  3. University of Kelaniya · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universidad Nacional de Salta:

Cite this brief

Drug Landscape (2026). Universidad Nacional de Salta — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-nacional-de-salta. Accessed 2026-05-17.

Related